RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Robert L. Copeland to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Robert L. Copeland has written about Parkinson Disease.
Robert L. Copeland
Connection Strength
0.948
Parkinson Disease
  1. Tizabi Y, Getachew B, Csoka AB, Manaye KF, Copeland RL. Novel targets for parkinsonism-depression comorbidity. Prog Mol Biol Transl Sci. 2019; 167:1-24.
    View in: PubMed
    Score: 0.598
  2. Getachew B, Csoka AB, Copeland RL, Manaye KF, Tizabi Y. Dihydromyricetin Protects Against Salsolinol-Induced Toxicity in Dopaminergic Cell Line: Implication for Parkinson's Disease. Neurotox Res. 2023 Apr; 41(2):141-148.
    View in: PubMed
    Score: 0.190
  3. Getachew B, Csoka AB, Bhatti A, Copeland RL, Tizabi Y. Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson's Disease. Neurotox Res. 2020 Oct; 38(3):596-602.
    View in: PubMed
    Score: 0.160
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support